MHRA authorises Diurnal’s CAH therapy Efmody
Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes
Read More
Tag: CAH
Diurnal seeks marketing authorisation for Chronocort in the UK
MHRA submission is based on same application filed with the EMA
Read More
Diurnal files Chronocort in the EU
If approved, the firm will be able to offer lifelong treatment for the rare condition congenital adrenal hyperplasia
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
